Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Hawkins J, Blakeslee S (2004). On Intelligence. Times Books: New York.
Hoffman RE, Woods SW, Hawkins KA, Pittman B, Tohen M, Preda A et al (2007). Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. Br J Psychiatry 191: 355–356.
Javitt DC (2009). When doors of perception close: bottom-up models of disrupted cognition in schizophrenia. Annu Rev Clin Psychol 5: 249–275.
Koethe D, Kranaster L, Hoyer C, Gross S, Neatby M, Schultze-Lutter F et al (2009). Binocular depth inversion as a paradigm of reduced visual information processing in prodromal state, antipsychotic-naïve and treated schizophrenia. Eur Arch Psychiatry Clin Neurosci 259: 195–202.
Kraus M, Keefe R, Krishnan R (2009). Memory-prediction errors and their consequences in schizophrenia. Neuropsychol Rev 19: 336–352.
Purves D, Lotto BR, Williams MS, Nundy S, Yang Z (2001). Why we see things the way we do: evidence for a wholly empirical strategy of vision. Philos Trans R Soc Lond Biol Sci 356: 285–297.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Richard Keefe, PhD reports that he currently or in the past 12 months has received investigator-initiated research funding support from the National Institute of Mental Health, Allon, GlaxoSmithKline, Novartis, Department of Veteran's Affairs, and the Singapore National Medical Research Council. He currently or in the past 12 months has received honoraria, served as a consultant, or advisory board member for Abbott, BiolineRx, BrainCells, BMS, Cypress Bioscience, Dainippon Sumitomo Pharma, Eli Lilly, EnVivo, Lundbeck, Merck, Pfizer, Roche, Shire, Solvay, and Takeda. Dr Keefe receives royalties from the Brief Assessment of Cognition in Schizophrenia (BACS) testing battery and the MATRICS Battery (BACS Symbol Coding). He is also a shareholder in NeuroCog Trials.
Michael Kraus has no disclosures to report.
Ranga Krishnan, MD reports that he has holdings in Orexigen and indirect holdings in Cenerx. He has consulted for Amgen, BMS, CeNeRx, Corcept, Eisai, GSK, J&J, Lundbeck, Merck, Organon, Pfizer, Spracor, and Wyeth in the past 12 months.
Rights and permissions
About this article
Cite this article
Keefe, R., Kraus, M. & Krishnan, R. Failures in Learning-Dependent Predictive Perception as the Key Cognitive Vulnerability to Psychosis in Schizophrenia. Neuropsychopharmacol 36, 367–368 (2011). https://doi.org/10.1038/npp.2010.153
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2010.153
This article is cited by
-
Cognitive Training for Impaired Neural Systems in Neuropsychiatric Illness
Neuropsychopharmacology (2012)